Lys-MDA

Last updated
Lys-MDA
Lys-MDA structure.png
Clinical data
ATC code
  • none
Identifiers
  • (2S)-2,6-diamino-N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]hexanamide
CAS Number
Chemical and physical data
Formula C16H25N3O3
Molar mass 307.394 g·mol−1
3D model (JSmol)
  • CC(Cc2ccc1OCOc1c2)NC(=O)C(N)CCCCN

Lys-MDA (Lysine-MDA, N-(L-lysinamidyl)-3,4-methylenedioxyamphetamine) is a substituted amphetamine derivative with empathogenic effects, which acts as a prodrug for MDA with a slower onset of effects and longer duration of action. Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment-resistant depression and post-traumatic stress disorder. New MDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland. [1] [2] [3] [4] A phase 1 clinical trial comparing MDMA, MDA, Lys-MDMA, and Lys-MDA has been completed as of August 2024. [5]

See also

References

  1. ↑ Buntz B (21 September 2022). "MindMed announces Phase 1 study of MDMA-like substances". Drug Discovery and Development.
  2. ↑ "MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances". Biospace.com. 20 September 2022.
  3. ↑ WO 2022/053696,Grill M,"Novel Safrylamine derivatives having prodrug properties.",published 17 March 2022, assigned to Compass Pathfinder Limited.
  4. ↑ WO 2023/283373,Clark S, Duncton MA,"Methylenedioxymethamphetamine and Related Psychedelics and Uses Thereof",published 12 January 2023, assigned to Terran Biosciences Inc.
  5. ↑ "ClinicalTrials.gov". ClinicalTrials.gov. 13 August 2024. Retrieved 13 November 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.